Cerebrovascular diseases

KANEKA CORPORATION: Sales Expansion of Brain Aneurysm Embolization Coils in the United States

Retrieved on: 
Friday, July 9, 2021
Health, Chemicals, Plastics, FDA, Medical devices, Surgery, Manufacturing, Other Manufacturing, Medical specialties, Neurosurgery, Cerebrovascular diseases, Branches of biology, Nervous system, Neurotrauma, Vascular diseases, Intracranial aneurysm, Aneurysm, Subarachnoid hemorrhage, Stroke, Kaneka Corporation

Inc., Kaneka intends to further expand the sales in the U.S. market from August 2021.

Key Points: 
  • Inc., Kaneka intends to further expand the sales in the U.S. market from August 2021.
  • Kaneka Medical America has been promoting the product at major stroke centers in the U.S., the worlds largest market.
  • It is deployed into the aneurysm through a catheter to prevent blood flow into the aneurysm.
  • A brain aneurysm is a bump that develops in an artery of the brain, and if it ruptures, it can cause subarachnoid hemorrhage.

Global Intracranial Aneurysm Market (2021 to 2028) - Share, Size, Trends, Industry Analysis Report - ResearchAndMarkets.com

Retrieved on: 
Tuesday, May 4, 2021
Health, Other Health, Medical specialties, Neurosurgery, Angiology, Cardiovascular system, Vascular diseases, Cerebrovascular diseases, Intracranial aneurysm, Aneurysm

b'The "Intracranial Aneurysm Market Share, Size, Trends, Industry Analysis Report, By Type, By End-Use; By Regions; Segment Forecast, 2021 - 2028" report has been added to ResearchAndMarkets.com\'s offering.\nThe global intracranial aneurysm market size is expected to reach USD 2.32 billion by 2028 according to a new study.

Key Points: 
  • b'The "Intracranial Aneurysm Market Share, Size, Trends, Industry Analysis Report, By Type, By End-Use; By Regions; Segment Forecast, 2021 - 2028" report has been added to ResearchAndMarkets.com\'s offering.\nThe global intracranial aneurysm market size is expected to reach USD 2.32 billion by 2028 according to a new study.
  • The report gives a detailed insight into current market dynamics and provides analysis on future market growth.\nMarket factors favoring the market growth for intracranial aneurysm include the world\'s aging population, rising prevalence of intracranial aneurysms, sedentary and busy lifestyles, increased funding, and grant on research and innovation.
  • This large section of the population is largely contributing to the market growth.
  • As per the estimates of the BAF, in the U.S. alone, every year around 30,000 people live with brain aneurysms.

Cerus Endovascular Announces IDE Approval from the U.S. FDA to Conduct Clinical Study of the Contour Neurovascular System™

Retrieved on: 
Wednesday, April 21, 2021
Medical specialties, Vascular diseases, Neurosurgery, Interventional radiology, Flow diverter, Prosthetics, Cerebrovascular diseases, Aneurysm, Intracranial aneurysm, Embolization, Alexander L. Coon

"The IDE study protocol closely aligns with protocols of other intra-saccular aneurysm repair devices that have received FDA approval.

Key Points: 
  • "The IDE study protocol closely aligns with protocols of other intra-saccular aneurysm repair devices that have received FDA approval.
  • Given the real-world patient outcomes we have experienced in Europe, where the Contour Neurovascular System has had CE mark approval since March 2020, we are hopeful that we will see similar, strong results from this trial.
  • "\nThe study, is designed to develop a robust data set to support the safety and efficacy of the Contour Neurovascular System for the endovascular embolization of wide-necked, bifurcated, saccular intracranial aneurysms.
  • The Company\'s CE Marked products, the Contour Neurovascular System and the Neqstent Coil Assisted Flow Diverter, expand the number and types of treatable intracranial aneurysms.

How Common Is Stroke in People Critically Ill with COVID-19?

Retrieved on: 
Friday, April 16, 2021
Stroke, Cerebrovascular diseases, Intracerebral hemorrhage, Health, COVID-19, Articles, Medical specialties

The preliminary study will be presented at the American Academy of Neurology\'s 73rd Annual Meeting being held virtually April 17 to 22, 2021.

Key Points: 
  • The preliminary study will be presented at the American Academy of Neurology\'s 73rd Annual Meeting being held virtually April 17 to 22, 2021.
  • "However, among the sickest of patients, those admitted to an ICU, our research found that stroke was not a common complication and that a stroke from a blood clot did not increase the risk of death.
  • However, people who had a stroke from a clot had no increased risk of death.\nOf the people with bleeding stroke, 72% died, but of those, only 15% died of stroke.
  • "Still, COVID-19 is a new disease and mutations have resulted in new variants, so it\'s important to continue to study stroke in people with the disease.

$4.16 Billion Neurovascular Intervention Devices Market - Global Forecast to 2027 - Acquisitions and Partnerships as a Part of the Growth Strategy

Retrieved on: 
Wednesday, March 10, 2021
Medical specialties, Vascular diseases, Cerebrovascular diseases, Gross pathology, Branches of biology, Organ systems, Neurosurgery, Stroke, Carotid artery stenosis, Intracranial aneurysm, Arteriovenous malformation, Aneurysm

DUBLIN, March 10, 2021 /PRNewswire/ -- The "Neurovascular Intervention Devices Global Market - Forecast To 2027" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • DUBLIN, March 10, 2021 /PRNewswire/ -- The "Neurovascular Intervention Devices Global Market - Forecast To 2027" report has been added to ResearchAndMarkets.com's offering.
  • The Neurovascular Intervention Devices global market is expected to grow at a high single digit CAGR to reach $4,167.4 million by 2027.
  • As a result of rapid advances, there is the great expansion in the potential therapeutic application for neurovascular diseases.
  • Neurovascular Interventional devices are used to treat intracranial aneurysm, ischemic stroke, arteriovenous malformation, carotid stenosis and other diseases like intracranial stenosis, dural fistula.

Lower-Profile Web Intrasaccular Aneurysm Treatment Device Receives FDA Approval

Retrieved on: 
Tuesday, January 12, 2021
Medical specialties, Vascular diseases, Gross pathology, Branches of biology, Neurosurgery, Clinical medicine, Aneurysm, Bifurcation, Cerebrovascular diseases, Flow diverter, Interventional radiology

The WEB System is a unique, single-device treatment solution for wide neck bifurcation aneurysms in a new category of devices called intrasaccular flow disruptors.

Key Points: 
  • The WEB System is a unique, single-device treatment solution for wide neck bifurcation aneurysms in a new category of devices called intrasaccular flow disruptors.
  • When placed inside the aneurysm sac, the WEB device's proprietary microbraid technology bridges the aneurysm neck, disrupting blood flow, and creates a scaffold for long-lasting treatment.
  • "The excellent clinical results we can achieve with intrasaccular flow disruption technology has changed the way we approach the treatment of wide neck bifurcation aneurysms, and the WEB 17 System expands upon that.
  • When placed inside the aneurysm sac, the WEB device's proprietary microbraid technology bridges the aneurysm neck, disrupting blood flow, and creates a scaffold for long-lasting treatment.

Amydis Announces Successful Completion of Pre-IND Meeting with the FDA for the Development of AMDX-2011P, a First-in-Class Retinal Tracer for the Diagnosis of Amyloid Angiopathy

Retrieved on: 
Monday, January 11, 2021
Neurotrauma, Medical specialties, Cerebrovascular diseases, Stroke, Branches of biology, Medicine, Intracerebral hemorrhage, Medical diagnosis, Bleeding

Amydis has reached agreement with the FDA on both nonclinical and clinical plans.

Key Points: 
  • Amydis has reached agreement with the FDA on both nonclinical and clinical plans.
  • CAA is a major cause of spontaneous intracerebral hemorrhage in people older than 55 and an important contributor to age-related cognitive decline.
  • I am keenly aware of the challenges CAA patients face in the diagnosis and treatment of disease.
  • I believe that diagnosis of CAA through the eye would be a tremendous step forward for the field.

BIOMODEX Announces Presentation of Data at SFNR 2020 Highlighting Benefits of Patient-Specific Rehearsals in Complex Unruptured Intracranial Aneurysms

Retrieved on: 
Thursday, December 17, 2020
Medical specialties, Medical imaging, Medicine, Branches of biology, Neurosurgery, Interventional radiology, Cerebrovascular diseases, Vascular diseases, Interventional Neuroradiology, Intracranial aneurysm, Aneurysm, Neuroradiology

Interventional neuroradiologists from France presented the results of a clinical study involving 20 patients at CHU Rennes with complex unruptured intracranial aneurysms.

Key Points: 
  • Interventional neuroradiologists from France presented the results of a clinical study involving 20 patients at CHU Rennes with complex unruptured intracranial aneurysms.
  • Using imaging scans, such as CTA and/or 3D rotational angiography, to visualize the inside of blood vessels and organs, Biomodex 3D-printed precise models of each individual patients' unruptured aneurysm.
  • Unlike silicone models, Biomodex models are created using biomechanical responsive advanced materials that simulate the characteristics and haptic feedback of the individual's anatomy.
  • Le Bras and Eugene presented at the 47 th Congress of the French Society of Neuroradiology SFNR on December 17, 2020.

Stroke Management Market Revenue to Cross USD 47B by 2026: Global Market Insights, Inc.

Retrieved on: 
Monday, September 28, 2020
Cardiovascular system, Angiology, Clinical medicine, RTT, Stroke, Thrombectomy, Vascular diseases, Cerebrovascular diseases

However, recent trials have stated thatthrombectomycan be helpful for patients even up to 24 hours after the stroke, thereby driving the market growth.

Key Points: 
  • However, recent trials have stated thatthrombectomycan be helpful for patients even up to 24 hours after the stroke, thereby driving the market growth.
  • Furthermore, the rising adoption of mobile stroke treatment units for treatment in stroke patients will enhance the industry's progression.
  • The stroke management market for the transientischemicattack (TIA) segment is expected to experience significant growth during the forecast period.
  • The carotid ultrasound segment in the stroke management market accounted for around USD 4 billion in 2019.

Seneca Biopharma, Inc. Announces Completion of Phase II Clinical Study in China for the Treatment of Ischemic Stroke

Retrieved on: 
Thursday, September 10, 2020
Stroke, Medical specialties, RTT, Ischemia, Thrombosis, Clinical medicine, Health, Cerebrovascular diseases, Silent stroke, Cerebrovascular disease

With this milestone achieved, the company remains on schedule to release top line data for the study during the fourth quarter of 2020.

Key Points: 
  • With this milestone achieved, the company remains on schedule to release top line data for the study during the fourth quarter of 2020.
  • Seneca Biopharma, Inc., is a clinical-stage biopharmaceutical company developing novel treatments for diseases of high unmet medical need.
  • Ischemic stroke, the most common type of stroke, occurs as a result of an obstruction within a blood vessel supplying blood to the brain.
  • Approximately 15 million people worldwide suffer stroke each year, of which approximately 87% are ischemic strokes.